Details of the Drug

General Information of Drug (ID: DMRV7H0)

Drug Name

Bumetanide

Synonyms

Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1], [2]

Therapeutic Class

Diuretics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

364.4

Topological Polar Surface Area (xlogp)

2.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg [5]
Elimination: 45% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 60 - 90 minutes [5]
Metabolism: The drug is metabolized via oxidation of the N-butyl side chain [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.45826 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.031% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.16 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.1 mg/mL [3]

Chemical Identifiers

Formula: C17H20N2O5S
IUPAC Name: 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
Canonical SMILES: CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
InChI: InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
InChIKey: MAEIEVLCKWDQJH-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2471
ChEBI ID: CHEBI:3213
CAS Number: 28395-03-1
DrugBank ID: DB00887
TTD ID: D0R7HO
VARIDT ID: DR00272
ACDINA ID: D00081

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 12 member 1 (SLC12A1)	TTS087L	S12A1_HUMAN	Blocker	[8], [9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Thiazide-sensitive sodium-chloride cotransporter (SLC12A3)	DT6MDC9	S12A3_HUMAN	Substrate	[10]
Monocarboxylate transporter 6 (SLC16A5)	DT3I124	MOT6_HUMAN	Substrate	[11]
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[12]
Organic anion transporter 4 (SLC22A11)	DT06JWZ	S22AB_HUMAN	Substrate	[13]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bumetanide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Carvedilol	DMHTEAO	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Carvedilol.	Heart failure [BD10-BD1Z]	[46]
Digitoxin	DMWVIGP	Moderate	Increased risk of hypomagnesemia by the combination of Bumetanide and Digitoxin.	Heart failure [BD10-BD1Z]	[47]
-----------

Coadministration of a Drug Treating the Disease Different from Bumetanide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Increased renal excretion of Bumetanide caused by Cefuroxime.	Acute bronchitis [CA42]	[48]
Framycetin	DMF8DNE	Major	Increased risk of nephrotoxicity by the combination of Bumetanide and Framycetin.	Alcoholic liver disease [DB94]	[49]
Cefamandole	DMNEXZF	Moderate	Increased renal excretion of Bumetanide caused by Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[48]
Dronedarone	DMA8FS5	Major	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Dronedarone.	Angina pectoris [BA40]	[50]
Cefotetan	DM07TX3	Moderate	Increased renal excretion of Bumetanide caused by Cefotetan.	Bacterial infection [1A00-1C4Z]	[48]
Ofloxacin	DM0VQN3	Minor	Decreased elimination of Bumetanide caused by Ofloxacin mediated competitive inhibition of renal tubular secretion.	Bacterial infection [1A00-1C4Z]	[51]
Kanamycin	DM2DMPO	Major	Increased risk of ototoxicity by the combination of Bumetanide and Kanamycin.	Bacterial infection [1A00-1C4Z]	[49]
Ceftizoxime	DM3VOGS	Moderate	Increased renal excretion of Bumetanide caused by Ceftizoxime.	Bacterial infection [1A00-1C4Z]	[48]
Cefoperazone	DM53PV8	Moderate	Increased renal excretion of Bumetanide caused by Cefoperazone.	Bacterial infection [1A00-1C4Z]	[48]
Cefprozil	DM7DSYP	Moderate	Increased renal excretion of Bumetanide caused by Cefprozil.	Bacterial infection [1A00-1C4Z]	[48]
Ceftriaxone	DMCEW64	Moderate	Increased renal excretion of Bumetanide caused by Ceftriaxone.	Bacterial infection [1A00-1C4Z]	[48]
Streptomycin	DME1LQN	Major	Increased risk of nephrotoxicity by the combination of Bumetanide and Streptomycin.	Bacterial infection [1A00-1C4Z]	[49]
Cefepime	DMHVWIK	Moderate	Increased renal excretion of Bumetanide caused by Cefepime.	Bacterial infection [1A00-1C4Z]	[48]
Cefpodoxime	DMJUNY5	Moderate	Increased renal excretion of Bumetanide caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[48]
Cefadroxil	DMMC345	Moderate	Increased renal excretion of Bumetanide caused by Cefadroxil.	Bacterial infection [1A00-1C4Z]	[48]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Bumetanide and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[52]
Cefazolin	DMPDYFR	Moderate	Increased renal excretion of Bumetanide caused by Cefazolin.	Bacterial infection [1A00-1C4Z]	[48]
Netilmicin	DMRD1QK	Major	Increased risk of nephrotoxicity by the combination of Bumetanide and Netilmicin.	Bacterial infection [1A00-1C4Z]	[49]
Cefditoren	DMSUVM1	Moderate	Increased renal excretion of Bumetanide caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[48]
Cefonicid	DMTX2BH	Moderate	Increased renal excretion of Bumetanide caused by Cefonicid.	Bacterial infection [1A00-1C4Z]	[48]
Cefradine	DMUNSWV	Moderate	Increased renal excretion of Bumetanide caused by Cefradine.	Bacterial infection [1A00-1C4Z]	[48]
Cefoxitin	DMYTXVR	Moderate	Increased renal excretion of Bumetanide caused by Cefoxitin.	Bacterial infection [1A00-1C4Z]	[48]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Bumetanide and Cariprazine.	Bipolar disorder [6A60]	[53]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of hypocalcemia by the combination of Bumetanide and Etidronic acid.	Bone paget disease [FB85]	[54]
Ceftibuten	DMWV2AG	Moderate	Increased renal excretion of Bumetanide caused by Ceftibuten.	Bronchitis [CA20]	[48]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Bumetanide when combined with Ketoprofen.	Chronic pain [MG30]	[55]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Levomilnacipran.	Chronic pain [MG30]	[56]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Sertraline.	Depression [6A70-6A7Z]	[56]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Vilazodone.	Depression [6A70-6A7Z]	[56]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Bumetanide and Selegiline.	Depression [6A70-6A7Z]	[57]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Vortioxetine.	Depression [6A70-6A7Z]	[56]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Bumetanide and Isocarboxazid.	Depression [6A70-6A7Z]	[57]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Milnacipran.	Depression [6A70-6A7Z]	[56]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Escitalopram.	Depression [6A70-6A7Z]	[56]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Desvenlafaxine.	Depression [6A70-6A7Z]	[56]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Bumetanide and OPC-34712.	Depression [6A70-6A7Z]	[53]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[58]
Nadolol	DMW6GVL	Moderate	Increased risk of hyperglycemia by the combination of Bumetanide and Nadolol.	Essential hypertension [BA00]	[46]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Bumetanide and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[52]
Metipranolol	DMJMVKI	Moderate	Increased risk of hypertriglyceridemia by the combination of Bumetanide and Metipranolol.	Glaucoma [9C61]	[46]
Levobetaxolol	DMSREPX	Moderate	Increased risk of hypertriglyceridemia by the combination of Bumetanide and Levobetaxolol.	Glaucoma [9C61]	[46]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hypertriglyceridemia by the combination of Bumetanide and Levobunolol.	Glaucoma [9C61]	[46]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Bumetanide and Procarbazine.	Hodgkin lymphoma [2B30]	[57]
Etelcalcetide	DMHP9BL	Major	Increased risk of hypocalcemia by the combination of Bumetanide and Etelcalcetide.	Hyper-parathyroidism [5A51]	[59]
Acebutolol	DM0TI4U	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Acebutolol.	Hypertension [BA00-BA04]	[46]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Bumetanide and Captopril.	Hypertension [BA00-BA04]	[60]
Penbutolol	DM4ES8F	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Penbutolol.	Hypertension [BA00-BA04]	[46]
Nebivolol	DM7F1PA	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Nebivolol.	Hypertension [BA00-BA04]	[46]
Pindolol	DMD2NV7	Moderate	Increased risk of hypertriglyceridemia by the combination of Bumetanide and Pindolol.	Hypertension [BA00-BA04]	[46]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of fluid/electrolyte loss by the combination of Bumetanide and Trichlormethiazide.	Hypertension [BA00-BA04]	[61]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of fluid/electrolyte loss by the combination of Bumetanide and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[61]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Bumetanide when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[55]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Bumetanide and ITI-007.	Insomnia [7A00-7A0Z]	[53]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[62]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Bumetanide and Ozanimod.	Multiple sclerosis [8A40]	[57]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Bumetanide and Promethazine.	Nausea/vomiting [MD90]	[53]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Bumetanide and Sibutramine.	Obesity [5B80-5B81]	[56]
Polythiazide	DMCH80F	Moderate	Increased risk of fluid/electrolyte loss by the combination of Bumetanide and Polythiazide.	Oedema [MG29]	[61]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[63]
Carboplatin	DMG281S	Moderate	Increased risk of ototoxicity by the combination of Bumetanide and Carboplatin.	Ovarian cancer [2C73]	[64]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Bumetanide when combined with Ibuprofen.	Pain [MG30-MG3Z]	[55]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Bumetanide and Safinamide.	Parkinsonism [8A00]	[57]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Bumetanide and Rasagiline.	Parkinsonism [8A00]	[57]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Bumetanide when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[55]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Bumetanide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[53]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Bumetanide when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[55]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Bumetanide and Quetiapine.	Schizophrenia [6A20]	[53]
Mesoridazine	DM2ZGAN	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Mesoridazine.	Schizophrenia [6A20]	[64]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Bumetanide and Aripiprazole.	Schizophrenia [6A20]	[53]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Iloperidone.	Schizophrenia [6A20]	[64]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Paliperidone.	Schizophrenia [6A20]	[64]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Bumetanide and Molindone.	Schizophrenia [6A20]	[53]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Bumetanide and Thiothixene.	Schizophrenia [6A20]	[53]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Amisulpride.	Schizophrenia [6A20]	[64]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Bumetanide and Asenapine.	Schizophrenia [6A20]	[53]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Pimozide.	Schizophrenia [6A20]	[65]
Cephapirin	DMV2JNY	Moderate	Increased renal excretion of Bumetanide caused by Cephapirin.	Sepsis [1G40-1G41]	[48]
Plazomicin	DMKMBES	Major	Increased risk of ototoxicity by the combination of Bumetanide and Plazomicin.	Urinary tract infection [GC08]	[49]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Bumetanide and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[53]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Bumetanide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[66]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Bumetanide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[67]
-----------


⏷ Show the Full List of 81 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bumetanide 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Bumetanide 1 mg tablet	1 mg	Oral Tablet	Oral
Bumetanide 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4837).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074225.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
9	Effect of L-ascorbate on chloride transport in freshly excised sinonasal epithelia. Am J Rhinol Allergy. 2009 May-Jun;23(3):294-9.
10	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
11	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
12	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
13	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
14	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
15	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
16	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
17	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
18	Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
19	Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
20	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
21	Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
22	Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
23	Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
24	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
25	Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
26	Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
27	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
28	The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
29	Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
30	Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
31	The role of the intracellular glutamate gradient in driving organic anion transporter function.
32	Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
33	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
34	Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505.
35	Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.
36	Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.
37	Inhibition of binding of [3H]metolazone to rat kidney membrane by stilbene disulfonates. Biochem Pharmacol. 1991 Jun 1;41(11):1745-50.
38	Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
39	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
40	Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
41	Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
42	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
43	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
44	Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
45	The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
46	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
47	Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
48	Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
49	Athlin L, Domellof L, Holm S "Gentamicin treatment in severe surgical infections: serum levels, interactions, toxicity and efficacy." Acta Chir Scand 147 (1981): 225-30. [PMID: 7034430]
50	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
51	Sudoh T, Fujimura A, Shiga T, Sasaki M, Harada K, Tateishi T, Ohashi K, Ebihara A "Renal clearance of lomefloxacin is decreased by furosemide." Eur J Clin Pharmacol 46 (1994): 267-9. [PMID: 8070509]
52	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
53	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
54	Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
55	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
56	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
57	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
58	Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
59	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
60	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
61	Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
62	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
63	Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
64	Cerner Multum, Inc. "Australian Product Information.".
65	Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
66	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
67	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]